Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT Pre-market 07:00:15 am
73.01 USD +0.83% Intraday chart for Gilead Sciences, Inc. 73.12 +0.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program DJ
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition MT
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc.. CI
Gilead Sciences Receives a Shareholder Proposal from John Chevedden CI
Gilead Sciences Receives a Shareholder Proposal from David Bahnsen CI
Gilead Sciences Receives a Shareholder Proposal from Jing Zhao CI
Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024 CI
Transcript : Gilead Sciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Transcript : Gilead Sciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 10:00 AM
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires MT
Health Care Up as Sector Gathers Upward Momentum -- Health Care Roundup DJ
Merck, Gilead Sciences Report Positive Data From Phase 2 Trial of Islatravir, Lenacapavir Combination in HIV MT
Gilead, Merck Report Positive Phase 2 Data on Weekly Oral HIV Combo DJ
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 CI
Gilead Sciences, Merus Collaborate to Discover New Potential Cancer Therapies MT
Gilead, Merus to Collaborate on Trispecific Antibody Research DJ
Gilead Sciences, Inc. and Merus N.V. Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers CI
Gilead Sciences Says Study Results Back Use of Veklury for People With COVID-19 MT
Gilead Sciences, Inc. Announces New Real-World Data Further Support the Use of Veklury for People Hospitalized with COVID-19 CI
Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health CI
Transcript : Gilead Sciences, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM
Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc. CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs RE
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating MT
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings RE
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
73.01 USD
Average target price
86.45 USD
Spread / Average Target
+18.41%
Consensus
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
  4. News Gilead Sciences, Inc.
  5. Morgan Stanley Downgrades Gilead Sciences to Equalweight From Overweight, Cuts Price Target to $74 From $84, Citing 'More Balanced Risk/Reward'